Skip to main navigation Skip to search Skip to main content

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

  • Paul Shaughnessy
  • , Miguel Islas-Ohlmayer
  • , Julie Murphy
  • , Maureen Hougham
  • , Jill MacPherson
  • , Kurt Winkler
  • , Matthew Silva
  • , Michael Steinberg
  • , Jeffrey Matous
  • , Sheryl Selvey
  • , Michael Maris
  • , Peter A. McSweeney
  • Texas Transplant Institute, San Antonio, TX, USA,
  • Rocky Mountain Blood and Marrow Transplant Program, Denver, CO, USA,
  • MCPHS University

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume114
Issue number22
DOIs
StatePublished - Nov 20 2009
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Surgery
  • Internal Medicine

Cite this